查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933366

全球重组白蛋白市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量、未来预测（2026-2034）

Recombinant Albumin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

重组白蛋白市场成长因子

预计2025年全球重组白蛋白市场规模将达到1506.7亿美元，2026年将成长至1592.6亿美元，最终在2034年达到2600.4亿美元，预测期内复合年增长率（CAGR）为6.05%。亚太地区将引领市场，预计2025年将占49.28%的市场占有率，这主要得益于慢性肾臟病率的上升、医疗保健支出的增加以及主要市场参与者之间的策略联盟。重组白蛋白是一种主要的血浆蛋白，它为人类来源的白蛋白提供了一种安全且可规模化生产的替代方案，可应用于药物递送、诊断、细胞培养补充剂等领域。

InVitria、富士胶片和光纯药株式会社以及赛多利斯股份公司等主要公司正在扩大其地域覆盖范围，并加大研发投入，以巩固其市场主导地位。策略合作和创新产品的推出进一步推动了市场成长，实现了适用于先进疗法的无病毒重组白蛋白的大规模生产。

市场动态

成长驱动因素：重组白蛋白在细胞和基因治疗领域应用的不断扩展是关键的成长驱动因素。它能够稳定敏感的治疗分子，提高细胞活力，并保护它们免受聚集和降解。例如，Albumedix 于 2021 年 2 月与 CGT Catapult 合作，共同研究用于先进治疗应用的白蛋白解决方案，这充分体现了其在该领域的重要性。

限制因素：供应限制对市场扩张构成挑战。重组白蛋白的生产需要复杂的表达系统、符合GMP规范以及昂贵的纯化技术，导致产量低、生产成本高。例如，三菱化学集团公司由于供应不稳定，于2022年7月停止了重组人血清的生产。

机会：先进药物递送系统（例如奈米白蛋白结合（nab）技术）的研发正在创造丰厚的市场机会。 nab技术可以提高低溶解度、高毒性药物的传递效率并减少副作用。例如，山德士公司于2024年10月推出了用于治疗转移性乳癌的紫杉醇白蛋白结合仿製药。

挑战：重组白蛋白的高成本限制了其广泛应用。 Optivmin 20 等产品的定价为每 100 毫升 1,660 美元，这反映了其复杂的生产和纯化工艺，限制了其广泛应用。

市场趋势

主要公司扩大产能是关键趋势。细胞和基因治疗领域对 GMP 级重组白蛋白的需求不断增长，推动了生产扩张方面的投资。例如，烟台普吉药业科技有限公司于 2025 年 3 月宣布了重组白蛋白生产扩建项目，显示市场成长势头强劲。

细分市场分析

依剂型划分：溶液剂型因其污染风险低、即用型配方和稳定性而占主导地位。 Invitria 于 2025 年 2 月推出了 Optibumin 25 溶液，为细胞和基因治疗领域的生物製造提供了安全的替代方案。

依应用领域划分：2024年，治疗领域占最大的市场占有率。重组白蛋白因其良好的生物相容性和稳定性，在治疗领域作为赋形剂和活性成分发挥着至关重要的作用。例如，2023年3月，Albumedix与Heartseed合作，开始为心臟再生细胞疗法供应Recombumin。

依最终用户划分：製药和生技产业是主要的最终用户，他们利用策略联盟、扩大生产规模和建立商业化合作伙伴关係。 2024年6月，Dyadic International与PHB达成合作，共同推动重组白蛋白的商业化，计画于2025年上市。

区域展望

亚太地区：受慢性病高发生率、医疗成本上升以及策略联盟的推动，预计到2025年，亚太市场规模将达到742.5亿美元。

北美地区：得益于强大的生物製药研发基础和符合GMP标准的生产设施，预计到2025年，北美市场将稳步增长至4450万美元，复合年增长率（CAGR）为5.08%。

欧洲：受先进研究和治疗应用需求的推动，预计到 2025 年，市场规模将达到 2,400 万美元，复合年增长率 (CAGR) 为 4.02%。

拉丁美洲、中东和非洲：预期成长温和，到 2025 年，拉丁美洲市场规模将达到 610 万美元，这主要得益于再生医学的普及和重组白蛋白使用量的增加。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 市场技术进步
  • 主要国家的监管状况（2025 年）
  • 主要公司产品线分析
  • 关键趋势：併购、业务合作等

第五章：全球重组白蛋白市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依剂型划分
    • 粉剂
    • 溶液
  • 市场分析、洞察与预测：依应用划分
    • 治疗
    • 诊断
    • 研究
  • 市场分析、洞察与预测：依最终用户划分
    • 医院和诊所
    • 製药和生物技术产业
    • 研究机构
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美重组白蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲重组白蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区重组白蛋白市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲重组白蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲重组白蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）国家
    • 南非
    • 中东其他地区非洲

第11章 竞争分析

  • 世界市场占有率分析(2025年)
  • 企业简介
  • InVitria
  • FUJIFILM Wako Pure Chemical Corporation
  • Orion Corporation
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
Product Code: FBI113883

Growth Factors of recombinant albumin Market

The global recombinant albumin market was valued at USD 150.67 billion in 2025 and is projected to grow to USD 159.26 billion in 2026, eventually reaching USD 260.04 billion by 2034, exhibiting a CAGR of 6.05% during the forecast period. Asia Pacific dominated the market in 2025 with a 49.28% share, driven by the increasing prevalence of chronic kidney diseases, rising healthcare expenditure, and strategic collaborations between major market players. Recombinant albumin, a key plasma protein, serves as a safer and scalable alternative to human-derived albumin, providing applications in drug delivery, diagnostics, and as a cell culture supplement.

Key players such as InVitria, FUJIFILM Wako Pure Chemical Corporation, and Sartorius AG are expanding their geographic presence and investing in research and development (R&D) to strengthen their market dominance. Strategic collaborations and innovative product launches further support the growth of the market, enabling large-scale production of virus-free recombinant albumin suitable for advanced therapeutics.

Market Dynamics

Drivers: The increasing application of recombinant albumin in cell and gene therapy is a major growth driver. It stabilizes sensitive therapeutic molecules, improves cell viability, and protects against aggregation or degradation. For instance, Albumedix collaborated with CGT Catapult in February 2021 to explore albumin-based solutions for advanced therapy applications, demonstrating its critical role in this sector.

Restraints: Supply limitations pose a challenge for market expansion. Manufacturing recombinant albumin requires advanced expression systems, GMP compliance, and costly purification technologies. These factors lead to low yields and high production costs. For example, Mitsubishi Chemical Group Corporation terminated its recombinant human serum production in July 2022 due to supply instability.

Opportunities: Research and development in advanced drug delivery systems, such as nanoparticle albumin-bound (nab) technology, is creating lucrative opportunities. Nab-technology improves delivery of low-solubility and high-toxicity drugs with fewer side effects. For instance, Sandoz launched a generic paclitaxel albumin-bound formulation in October 2024 for metastatic breast cancer therapy.

Challenges: The high cost of recombinant albumin limits adoption. Products like Optibumin 20 are priced at USD 1,660 for 100 mL, reflecting the complex production and purification processes involved, which hampers widespread usage.

Market Trends

An important trend is the expansion of manufacturing capacity by key players. Increasing demand for GMP-grade recombinant albumin in cell and gene therapies has driven investments in production scale-up. For example, Yantai Projiji Pharmaceutical Technology Co., Ltd. announced a recombinant albumin expansion project in March 2025, demonstrating market growth momentum.

Segmentation Analysis

By Dosage Form: The solution segment dominates due to lower contamination risk, ready-to-use formulations, and consistency. InVitria launched Optibumin 25 solution in February 2025, offering a safe alternative for biomanufacturing in cell and gene therapy.

By Application: The therapeutic segment captured the largest share in 2024. Recombinant albumin is essential as an excipient and active component in therapies due to its biocompatibility and stability. For example, Albumedix collaborated with Heartseed in March 2023 to supply Recombumin for cardiac remuscularization cell therapy.

By End-User: Pharmaceutical and biotechnology industries dominate as end-users, leveraging strategic collaborations, expanded manufacturing, and commercialization partnerships. In June 2024, Dyadic International partnered with PHB to commercialize recombinant albumin, with launches expected in 2025.

Regional Outlook

Asia Pacific: Dominated the market in 2025 with USD 74.25 billion, driven by chronic disease prevalence, rising healthcare expenditure, and strategic collaborations.

North America: Expected steady growth at a 5.08% CAGR, with USD 44.5 million in 2025, driven by a strong biopharma R&D base and GMP-compliant manufacturing facilities.

Europe: Projected growth at 4.02% CAGR, reaching USD 24.0 million in 2025, supported by advanced research and demand in therapeutic applications.

Latin America & Middle East & Africa: Moderate growth is expected, with Latin America reaching USD 6.1 million in 2025, aided by regenerative medicine adoption and increasing recombinant albumin usage.

Competitive Landscape

The market is concentrated, dominated by Sartorius AG, FUJIFILM Wako Pure Chemical Corporation, and InVitria. Their strong global presence, product portfolios, and strategic collaborations reinforce market leadership. Other key players include Thermo Fisher Scientific, Merck KGaA, and Orion Corporation. Notable developments include:

  • August 2023: Dyadic International announced positive testing results for animal-free recombinant albumin.
  • August 2022: Sartorius AG acquired Albumedix for USD 449.13 million.
  • July 2025: Wuhan Healthgen Biotechnology received approval for rice-derived recombinant human albumin injection in China.

Conclusion

The global recombinant albumin market is expected to grow from USD 150.67 billion in 2025 to USD 159.26 billion in 2026, reaching USD 260.04 billion by 2034 at a CAGR of 6.05%. Growth is driven by its widespread applications in therapeutics, cell and gene therapy, and advanced biologics manufacturing. Asia Pacific leads the market due to rising chronic disease prevalence and strategic collaborations. Despite challenges like high costs and supply limitations, R&D investments, manufacturing expansion, and drug delivery innovations are anticipated to drive significant market growth, making it a lucrative opportunity for major players and new entrants alike.

Segmentation By Dosage Form

  • Powder
  • Solution

By Application

  • Therapeutics
  • Diagnostics
  • Research

By End User

  • Hospital & Clinics
  • Pharmaceutical & Biotechnology Industry
  • Research Institutes

By Geography

  • North America (By Dosage Form, Application, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Dosage Form, Application, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Dosage Form, Application, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Dosage Form, Application, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Dosage Form, Application, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Technological Advancements in the Market
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2025
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Key Industry Developments- Mergers, Acquisitions, Partnerships, etc.

5. Global Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.1.1. Powder
    • 5.1.2. Solutions
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Therapeutics
    • 5.2.2. Diagnostics
    • 5.2.3. Research
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospital & Clinics
    • 5.3.2. Pharmaceutical & Biotechnology Industry
    • 5.3.3. Research Institutes
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.1.1. Powder
    • 6.1.2. Solution
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Therapeutics
    • 6.2.2. Diagnostics
    • 6.2.3. Research
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospital & Clinics
    • 6.3.2. Pharmaceutical & Biotechnology Industry
    • 6.3.3. Research Institutes
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.1.1. Powder
    • 7.1.2. Solution
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Therapeutics
    • 7.2.2. Diagnostics
    • 7.2.3. Research
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospital & Clinics
    • 7.3.2. Pharmaceutical & Biotechnology Industry
    • 7.3.3. Research Institutes
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.1.1. Powder
    • 8.1.2. Solution
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Therapeutics
    • 8.2.2. Diagnostics
    • 8.2.3. Research
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospital & Clinics
    • 8.3.2. Pharmaceutical & Biotechnology Industry
    • 8.3.3. Research Institutes
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.1.1. Powder
    • 9.1.2. Solution
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Therapeutics
    • 9.2.2. Diagnostics
    • 9.2.3. Research
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospital & Clinics
    • 9.3.2. Pharmaceutical & Biotechnology Industry
    • 9.3.3. Research Institutes
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 10.1.1. Powder
    • 10.1.2. Solution
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Therapeutics
    • 10.2.2. Diagnostics
    • 10.2.3. Research
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospital & Clinics
    • 10.3.2. Pharmaceutical & Biotechnology Industry
    • 10.3.3. Research Institutes
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Product, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. InVitria
    • 11.2.2. FUJIFILM Wako Pure Chemical Corporation
    • 11.2.3. Orion Corporation
    • 11.2.4. Sartorius AG
    • 11.2.5. Thermo Fisher Scientific Inc.
    • 11.2.6. Merck KGaA

List of Tables

  • Table 1: Global Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 2: Global Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 3: Global Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 4: Global Recombinant Albumin Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 5: North America Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 6: North America Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 7: North America Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 8: North America Recombinant Albumin Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 9: Europe Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 10: Europe Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 11: Europe Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 12: Europe Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 14: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 15: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 16: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 18: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 19: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 20: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 22: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 23: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 24: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Recombinant Albumin Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Recombinant Albumin Market Value Share (%), by Dosage Form, 2025 & 2034
  • Figure 3: Global Recombinant Albumin Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Recombinant Albumin Market Value Share (%), by End User, 2025 & 2034
  • Figure 5: Global Recombinant Albumin Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Recombinant Albumin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 7: North America Recombinant Albumin Market Value Share (%), by Dosage Form, 2025
  • Figure 8: North America Recombinant Albumin Market Value (USD million), by Application, 2025 & 2034
  • Figure 9: North America Recombinant Albumin Market Value Share (%), by Application, 2025
  • Figure 10: North America Recombinant Albumin Market Value (USD million), by End User, 2025 & 2034
  • Figure 11: North America Recombinant Albumin Market Value Share (%), by End User, 2025
  • Figure 12: North America Recombinant Albumin Market Value (USD million), By Country, 2025 & 2034
  • Figure 13: North America Recombinant Albumin Market Value Share (%), By Country, 2025
  • Figure 14: Europe Recombinant Albumin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 15: Europe Recombinant Albumin Market Value Share (%), by Dosage Form, 2025
  • Figure 16: Europe Recombinant Albumin Market Value (USD million), by Application, 2025 & 2034
  • Figure 17: Europe Recombinant Albumin Market Value Share (%), by Application, 2025
  • Figure 18: Europe Recombinant Albumin Market Value (USD million), by End User, 2025 & 2034
  • Figure 19: Europe Recombinant Albumin Market Value Share (%), by End User, 2025
  • Figure 20: Europe Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Recombinant Albumin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 23: Asia Pacific Recombinant Albumin Market Value Share (%), by Dosage Form, 2025
  • Figure 24: Asia Pacific Recombinant Albumin Market Value (USD million), by Application, 2025 & 2034
  • Figure 25: Asia Pacific Recombinant Albumin Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Recombinant Albumin Market Value (USD million), by End User, 2025 & 2034
  • Figure 27: Asia Pacific Recombinant Albumin Market Value Share (%), by End User, 2025
  • Figure 28: Asia Pacific Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Recombinant Albumin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 31: Latin America Recombinant Albumin Market Value Share (%), by Dosage Form, 2025
  • Figure 32: Latin America Recombinant Albumin Market Value (USD million), by Application, 2025 & 2034
  • Figure 33: Latin America Recombinant Albumin Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Recombinant Albumin Market Value (USD million), by End User, 2025 & 2034
  • Figure 35: Latin America Recombinant Albumin Market Value Share (%), by End User, 2025
  • Figure 36: Latin America Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Recombinant Albumin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 39: Middle East & Africa Recombinant Albumin Market Value Share (%), by Dosage Form, 2025
  • Figure 40: Middle East & Africa Recombinant Albumin Market Value (USD million), by Application, 2025 & 2034
  • Figure 41: Middle East & Africa Recombinant Albumin Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Recombinant Albumin Market Value (USD million), by End User, 2025 & 2034
  • Figure 43: Middle East & Africa Recombinant Albumin Market Value Share (%), by End User, 2025
  • Figure 44: Middle East & Africa Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Recombinant Albumin Market Share (%), By Company, 2025